Background: Vaccination programs reduce the
INTRODUCTION
The combined reduced-antigen content tetanus, diphtheria, and acellular pertussis (Tdap) vaccine is a single-dose booster vaccine that not only maintains the standard of care for tetanus and diphtheria protection but also reduces pertussis morbidity [1] [2] [3] [4] [5] [6] [7] . Erythema nodosum is a reactive erythema that can be associated with infections, drugs, and many conditions [8] [9] [10] [11] [12] ; however, the new onset of erythema nodosum after receiving a vaccine is rare. A young woman who developed erythema nodosum after receiving Tdap vaccine is reported and vaccinations that have been associated with erythema nodosum have been summarized.
CASE REPORT
A healthy 39-year-old Japanese woman visited her primary care physician for an annual examination. She had received all of her childhood vaccinations without any complications. She did not have any history of preceding infections, sore throat or diarrhea.
She also had no prior or current skin or systemic diseases and her laboratory studies were normal.
There was no personal or family history of tuberculosis. Her physician recommended prophylactic vaccination with combined tetanus-diphtheria-pertussis (Tdap) vaccine since her booster immunization was due.
Informed consent was obtained from the patient for being included in the study and for the publishing of photographs. This article does not contain any studies with human subjects performed by the author. (Fig. 1 ). There was a large, 12 by 8 cm, erythematous nodule on distal pretibial left leg (Fig. 1) .
Multiple, individual and grouped, nodules were present on her right leg; they were located on the distal lateral thigh (4.0 by 2.5 cm), the proximal lateral calf (6.0 by 3.5 cm), the distal lateral calf (2.0 by 2.0 cm), and the distal lateral leg proximal to the ankle (each of 3 lesions measuring 2.5 by 2.5 cm) (Fig. 2) .
Correlation of her medical history, clinical symptoms, and lesion morphology were compatible with a diagnosis of Tdap vaccine- 
DISCUSSION
The morbidity and mortality from the bacterial diseases diphtheria, pertussis and, tetanus have been dramatically reduced secondary to vaccination programs beginning in infancy [1] [2] [3] [4] [5] [6] [7] . The originally developed infant combined diphtheria-tetanus-whole-cell pertussis (DTwP) vaccine was subsequently supplanted by the infant combined diphtheriatetanus-acellular pertussis (DTaP) vaccine that is less reactogenic [1, 2] . Combined reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine is well tolerated in all age groups [1] [2] [3] [4] [5] [6] [7] . The most common adverse events associated with Tdap vaccine administration are local injection-site reactions such as pain, redness, swelling, and increased upper-arm circumference [1] [2] [3] [4] [5] [6] [7] . Headache, fatigue, gastrointestinal symptoms and fever are the most frequent systemic events [1] [2] [3] [4] [5] [6] [7] . These adverse events occur in up to approximately 20 percent of individuals, are only mild or moderate in intensity, and are typically transient [1] [2] [3] [4] [5] [6] [7] .
Serious adverse events following Tdap immunization are rare [5] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . To the best of my knowledge, the currently described woman is the first individual in whom erythema nodosum has been reported following vaccination with Tdap.
Her symptoms and lesions began within 48 h after she was vaccinated; she had no conditions that have previously been noted to cause erythema nodosum and she was not taking any medication that has previously been associated with the development of erythema nodosum.
The lesion-associated tenderness and the nodules both began to resolved within 3 days after initiating oral treatment with a corticosteroid and a long-acting antihistamine daily, and a nonsteroidal anti-inflammatory agent four times each day. During the next 1 weeks, her symptoms resolved and all but one of the nodules had completely cleared.
The onset of clinical symptoms and skin lesions is variable in patients with vaccineassociated erythema nodosum. Similar to the a Bacille-Calmette-Guerin (BCG) vaccine, a live attenuated vaccine derived from attenuated strains of Mycobacterium bovis, is used to prevent tuberculosis [13] . A retrospective study of etiologic factors associated with erythema nodosum in children was performed; BCG vaccination was the related etiology in 1 of 45 patients [14] . Another patient developed erythema nodosum 30 days after BCG vaccination; the local inflammatory reaction caused by the vaccine was normal [15] b Erythema nodosum has been associated with administration of hepatitis B vaccine prepared either from human serum [20] e An 11-year-old girl developed erythema nodosum at the site of a dog bite after receiving a vaccination against rabies [22] . Another patient, 35-year-old woman developed biopsy-confirmed erythema nodosum a few days after receiving the second dose of a rabies vaccine treatment: Rabipur Ò (Novartis Vaccines and Diagnostics, Cambridge, MA, USA), a purified chick embryo/second generation tissue culture vaccine [21] f Three patients are reported who developed cutaneous eruptions that were essentially varioliform, but ranged from erythema multiforme and erythema nodosum to severe hemorrhagic exanthems, on the 14th, 20th, and 22nd day after primary vaccination [23] g A 39-year-old woman developed erythema nodosum within 48 h after receiving a dose of the combined reduced-antigen content tetanus, diphtheria, and acellular pertussis (Tdap) vaccine [current report] h A 56-year-old woman developed pain and stiffness in both ankles, knees and lower back 24 h after receiving 0.5 ml of typhoid vaccine (to prevent salmonella infection) and 1.0 ml of cholera vaccine (to prevent cholera infection) intramuscularly; the symptoms were followed by the development of classical erythema nodosum on the anterior aspects of both lower legs [24] [17] . In addition, the woman who had previously received a course of typhoid and cholera vaccine more than 5 years earlier, developed symptoms 24 h after her booster vaccination followed by classic appearing erythema nodosum lesions on her anterior lower legs [24] ; similar to this patient, erythema nodosum developed within a few days after the second dose of rabies vaccine [21] and 15 days after the second injection of human papillomavirus vaccine (and subsequently 10 days after the third injection of Gardiasil 4 months later) [19] . In contrast, vaccine-related erythema nodosum appeared 18, 14-22, and 30 days after vaccination with malaria [20] , small pox [23] , or BacilleCalmette-Guerin [15] , respectively.
The pathogenesis of vaccine-related erythema nodosum remains to be established.
Many of the investigators favor the development of erythema nodosum being secondary to the antigen of the infectious disease. However, it is impossible to absolutely exclude the possibility of a hypersensitivity reaction to one or more of the adjuvant components used to prepare the vaccine.
CONCLUSION
The new onset of erythema nodosum after receiving vaccination is uncommon, but has been reported following vaccination for cholera, hepatitis B, human papillomavirus, malaria, rabies, small pox, tuberculosis, and typhoid [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . This is the first report of erythema nodosum occurring after Tdap vaccination for the prevention of tetanus, diphtheria, and pertussis. It is important for clinicians to be aware of this rare, yet potential, adverse effect to Tdap vaccine.
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